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A cute liver failure (ALF),  or fulminant hepatic failure,  is characterized by a deterioration of liver 
function and hepatic encephalopathy in the absence of 
preexistent disease [1].  ALF can rapidly lead to death 
due to multiorgan failure,  septic complications,  and 
cerebral edema [1 , 2].  Prior to the advent of liver trans-
plantation (LT),  the ALF mortality rates with support-
ive medical therapy were reported to range from 80% to 
85%.  In addition,  the early post-transplant prognosis 
for ALF was worse than that of other chronic liver dis-
ease [3].  Over the last 3 decades,  advancements in 
critical care management and transplant surgical proce-
dures have improved the transplant prognosis to 
60-80% [4-6].
Patients with ALF can be listed as a United Network 
for Organ Sharing (UNOS) status 1A (urgent) patient in 
the U.S.  and as “super urgent” in the UK,  and approxi-
mately 50% of such patients can undergo LT.  ALF 
patients accounts for less than 10% of all LTs in the U.S.  
and approximately 11% in Europe,  but two-thirds of the 
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Determining the indications for and timing of liver transplantation (LT) for acute liver failure (ALF) is essen-
tial.  The King’s College Hospital (KCH) guidelines and Japanese guidelines are used to predict the need for LT 
and the outcomes in ALF.  These guidelines’ accuracy when applied to ALF in different regional and etiological 
backgrounds may differ.  Here we compared the accuracy of new (2010) Japanese guidelines that use a simple 
scoring system with the 1996 Japanese guidelines and the KCH criteria for living donor liver transplantation 
(LDLT).  We retrospectively analyzed 24 adult ALF patients (18 acute type,  6 sub-acute type) who underwent 
LDLT in 1998-2009 at our institution.  We assessed the accuracies of the 3 guidelines’ criteria for ALF.  The over-
all 1-year survival rate was 87.5%.  The new and previous Japanese guidelines were superior to the KCH criteria 
for accurately predicting LT for acute-type ALF (72% vs. 17%).  The new Japanese guidelines could identify 13 
acute-type ALF patients for LT,  based on the timing of encephalopathy onset.  Using the previous Japanese 
guidelines,  although the same 13 acute-type ALF patients (72%) had indications for LT,  only 4 patients were 
indicated at the 1st step,  and it took an additional 5 days to decide the indication at the 2nd step in the other 9 
cases.  Our findings showed that the new Japanese guidelines can predict the indications for LT and provide a 
reliable alternative to the previous Japanese and KCH guidelines.
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LTs in Asia [7 , 8].  In the context of organ donor short-
ages,  living donor liver transplantation (LDLT) can be 
an alternative radical procedure [9-15].  Two essential 
tasks in the treatment of ALF are to determine: (1) 
whether the patient’s liver function will recover or not,  
and (2) the indication for and the timing of LT before a 
fatal outcome occurs [4 , 6 , 16 , 17].  Criteria for these 
tasks were first reported by Clichy and O’Grady,  and 
these are known as the Clichy criteria and the King’s 
College Hospital criteria,  respectively.  The Clichy crite-
ria were initially widely adopted in Europe,  but because 
of their limitations,  the King’s College Hospital criteria 
are now widely and preferably applied [18].  We con-
ducted the present retrospective study with two goals:  
(1) to determine the accuracy of new (2010) Japanese 
guidelines that use a simple scoring system for LT in 
ALF patients (particularly in patients with acute-type 
ALF) in a comparison with the previous (1996) Japanese 
guidelines and the King’s College Hospital guidelines,  
and (2) to clarify the prognostic factors after LDLT for 
ALF on the basis of transplant outcome.
Patients and Methods 
Patients. We investigated the cases of the 24 con-
secutive adult patients undergoing LDLT for ALF at 
Okayama University Hospital (Okayama,  Japan) 
between August 1998 and December 2009.  The popula-
tion was comprised of 14 men and 10 women,  and the 
mean age was 36.5 ± 11.8 years (range,  19-63 years).  
During the same period,  we performed LDLT for 212 
patients with non-ALF liver disease.  We performed a 
retrospective analysis and re-evaluation of the indica-
tions for LT for this total patient cohort.  The pre- and 
post-transplantation data included recipient demo-
graphics,  donor factors,  operative variables,  and 
post-transplant outcomes.  We also re-evaluated the 
indication for LT using the new Japanese guidelines 
[19],  in addition to the other previous criteria.  
Re-evaluated data were verified about the integrity 
between each criterion.  The study protocol was 
approved by the Ethics Committee of the Okayama 
University Hospital (#854).
Diagnosis of acute liver failure and indication for 
liver transplantation. During the study period 
August 1998 to December 2009,  we used the Japanese 
diagnostic guidelines and indication criteria for “fulmi-
nant hepatitis”.  According to these criteria,  fulminant 
hepatitis is defined as: 1) hepatitis in which hepatic 
encephalopathy of coma grade greater than II develops 
in the patients within 8 weeks after the onset of disease 
symptoms,  and (2) highly deranged liver function 
showing prothrombin time < 40% of the standardized 
values is observed.  Fulminant hepatitis is classified into 
two subtypes: the acute type and subacute type,  in 
which the encephalopathy occurs within 10 days or later 
than 11 days,  respectively.  We excluded patients with-
out the appearance of hepatitis or with the histology of 
ALF due to fulminant Wilson’s disease,  drug toxicity,  
circulatory disturbance or acute fatty liver of pregnancy.  
We considered the indications for LT based on the fol-
lowing indication criteria for LT: (i) the national 
guidelines by the Japanese Acute Hepatic Failure Study 
Group [20],  and (ii) the King’s College Hospital’s crite-
ria [6].  In the Japanese guidelines,  historically the 
treatment strategy for all patients was considered based 
on previous Japanese criteria.  The details of criteria are 
described in Fig. 1.  In addition,  if artificial liver sup-
port,  such as plasmapheresis,  did not contribute to 
recovery,  the timing for the LT indication was acceler-
ated in order to avoid progression to irreversible brain 
damage or systemic fatal complications.  In other words,  
we emphasized the degree of hepatic atrophy,  the pro-
gression of hepatic encephalopathy,  and the respon-
siveness to critical care.  All treatment modalities and 
the indications for LT were conducted after obtaining 
informed consent and after obtaining approval of the 
Liver Transplantation Committee of Okayama University 
Hospital.
Surgical procedure. The surgical technique and 
postoperative care were conducted as described,  with 
minor modifications [21-23].  The volume of the 
resected donor liver segment was calculated before sur-
gery by computed tomography (CT) volumetry.  The 
choice of resected segments for donation was dictated 
by the need to leave a sufficient remnant liver volume of 
more than approximately 35% of the donor’s liver vol-
ume.  The resected segments included the left lobe,  
extended left lobe with left caudate lobe,  and the right 
lobe.  For the donor procedure,  parenchymal dissection 
was performed without an inflow occlusion of the 
Glissonian pedicle of the liver graft.  The liver graft was 
flushed and preserved in cold UW (University of 
Wisconsin) solution.  For the recipient procedure,  the 
native liver was resected,  preserving the inferior vena 
cava.  In the anhepatic phase,  any massive hemorrhage 
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Fig. 1　 Indication criteria for liver transplantation.  A,  Kingʼs College Hospital criteria; B,  Guidelines for liver transplantation for fulminant 
hepatitis in Japan (1996); C,  Scoring system to predict the mortality of patients with fulminant hepatitis and late-onset hepatic failure 
(LOHF) established by the Acute Liver Failure Study Group of Japan (2010).
from the perihepatic area was almost completely 
stanched.  After the hepatic and portal veins were 
reconstructed,  the hepatic artery was anastomosed 
under microscopy.  The biliary tract was reconstructed 
by a Roux-en-Y hepatico-jejunostomy or duct-to-duct 
hepatico-choledochostomy.  The endotracheal tube was 
removed when the patient recovered consciousness.
The initial immunosuppressive regimen consisted of 
tacrolimus or cyclosporine and a short course of ste-
roids that was tapered over 3-6 months.  Tacrolimus and 
cyclosporine were started at 0.12 mg/kg/day,  or 6 to 
8 mg/kg/day,  via a nasogastric feeding tube.  The dos-
age was carefully adjusted according to the drug trough 
level with targeting trough levels of 10-15 ng/ml for 
tacrolimus and 200-250 ng/ml for cyclosporine.  Whole 
blood tacrolimus or cyclosporine drug trough levels 
were measured 12hr after the administration of the drug 
and every morning during the postoperative acute 
phase.
Statistical analysis. Nonparametric methods were 
used for the inferential analysis.  The continuous vari-
ables were evaluated using the Mann-Whitney U-test,  
and categorical data were compared by the chi-square 
test.  Overall survival rates were estimated by the 
Kaplan-Meier method and were compared with the 
other LDLT patients using the log rank test.  All statisti-
cal analyses were performed with JMP software 
(Release 6.0.3,  SAS Institute Japan,  Tokyo,  Japan).  
P-values < 0.05 were regarded as indicating statistical 
significance.
Results
The patient demographics are summarized in Table 1.  
The mean and median ages at LDLT were 40.2 and 36.5 
years,  respectively (range,  19-65 years).  The most 
common cause of ALF etiology was unknown (12 cases,  
50%),  followed by hepatitis B virus infection (9 cases,  
37.5%),  drug-induced (2 cases,  8.3%),  and hepatitis C 
virus infection (1 case,  4.2%).  The mean time from the 
onset of jaundice was 5 days (range 1-56 days).  The 
mean and median times from the onset of jaundice to 
the development of coma were 11.2 and 5 days,  respec-
tively; therefore,  patients were categorized into 2 sub-
types (18 acute types,  6 sub-acute types),  according to 
Japanese diagnostic guidelines.  The volume calculator 
in CT showed visible liver atrophy in 23 cases.  The 
grades of hepatic encephalopathy were 8 cases of 
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Table 1　 Patient demographics
Variables Values
Preoperative factors
Age (years) 36.5 (19-63)
Gender
　Male : Female 16 : 8
Etiology
　Viral hepatitis : Drug induced : Unknown 10 : 2 : 12
Disease Type
　Acute type : sub-acute type : LOHF 18 : 5 : 1
O-C (days) 5 (1-56)
PT (%) 23 (10-43)
T. bilirubin (mg/dL) 11.0 (3.1-30.0)
D/T ratio 0.50 (0.09-0.82)
Platelet count (104/µL) 7.85 (1.4-24.4)
Grade of encephalopathy
　II : III : IV 8 : 13 : 3
Donor and graft factors
Donor age (years) 38 (21-63)
Donor gender
　Male : Female 15 : 9
ABO compatibility
　Identical : compatible : incompatible 17 : 6 : 1
Donor relation
　Patients : Siblings : Children : Spouse 7 : 7 : 7 : 3
Graft type
　Right lobe : Left lobe : Posterior sector 14 : 9 : 1
GW/RBW ratio
Donor blood loss (mL/kg)
0.05a
16.7±10.1
Postoperative complications
　Bile leak : Wound infection : None 3 : 2 : 19
Operative and post-operative factors
Operating time (min) 500 (340-835)
Recipient blood loss (mL/kg) 5.0 (1-56)
Time to extubation (hours)
　Mean/Median (range) 73/92 (11-449)
†Values are expressed as mean ± standard deviation (S.D.).
aWilcoxon signed-rank test,  bχ2 test
D/T ratio,  ratio of direct to total bilirubin concentration; GW/RBW 
ratio,  ratio of donor graft weight to recipient body weight; LOHF,  
late onset hepatic failure; O-C,  the interval between hepatitis onset 
and hepatic encephalopathy development; PT,  prothrombin 
time; TB,  total bilirubin; PLT,  platelet count.
grade II,  13 cases of grade III,  and 3 cases of grade IV.  
All cases of grade IV and 10 cases of grade III had rapid 
deterioration despite intensive liver supportive treat-
ment,  of which 9 cases needed intubation before LT.
In regard to operative factors,  the mean and median 
donor age were 40.2 and 38.5 years,  respectively (range,  
21-63 years).  The grafts consisted of the right lobe in 14 
cases,  the left lobe with caudate lobe in 9 cases,  and the 
posterior sector graft in one case.  The graft weight to 
recipient’s body weight ratio (GW/RBW) ranged from 
0.59 to 1.43 (median,  0.95).  All living donor were rela-
tives of the recipient (i.e.,  parent,  spouse,  or sibling).  
ABO-identical pairs or compatible pairs were favored,  
but one case was transplanted from an ABO-
incompatible donor using a protocol composed of pre-
operative treatment plasma exchange,  an anti-CD20 
targeting agent,  and a postoperative portal venous 
infusion of steroid.  The operation time and blood loss 
values were comparable to those of LDLTs for non-ALF 
disease (data not shown).
Concerning postoperative prognosis,  three recipi-
ents had fatal outcomes in the early post-operative 
phase.  Their causes of death were postoperative septic 
complications,  secondary biliary complications,  and 
fungal infection.  The hospital mortality rate was 12.5%.  
The three fatal cases were categorized as acute-type ALF,  
and they had significantly higher donor age and small-
er-sized grafts compared to those of the 21 survivors 
(Table 2).  All survivors completely recovered from 
physical deterioration and did not develop permanent 
neurologic complications,  except for the single ABO-
incompatible case with subarachnoid and intra-cerebral 
hemorrhage.
We compared the sensitivities of three sets of prog-
nostic criteria in ALF: the King’s College criteria,  the 
previous (1996) Japanese guidelines and the new (2010) 
Japanese guidelines.  With the use of the King’s College 
Hospital criteria,  LT was indicated for 8 patients (33.3%) 
needed LT: 3 acute-type patients and five sub-acute-
type patients.  The new Japanese guidelines indicated 
that 19 patients (79.2%) needed LT: 13 acute-type and 
all 6 sub-acute-type patients.  These 19 patients include 
11 patients who could not be censored for the indica-
tion of LT by the King’s College criteria.  The accuracy of 
these new Japanese guidelines was equal to that of the 
previous guidelines,  especially in patients with sub-
acute-type ALF.
However,  by the previous Japanese guidelines,  LT 
was indicated at the 1st step for only 4 patients (16.6%),  
and it took an additional five days to decide the indica-
tion at the 2nd step in the other 9 acute-type cases.  
Thus,  the new Japanese guidelines were superior to both 
the King’s College Hospital criteria and the previous 
Japanese guidelines in terms of the accuracy of the indi-
cation for LT,  especially in patients with acute-type 
ALF.  Further,  the indications for LT could be assessed 
by the new Japanese guidelines thorough a simple scor-
ing system at the time point of the onset of encephalop-
athy (Fig. 2).
Discussion
ALF is a life-threatening disease characterized by the 
deterioration of liver function in response to the rapid 
death or injury of a large portion of hepatocytes.  This 
phenomenon is associated with a dismal prognosis (80-
85% mortality) [3].  The outcome of ALF is significantly 
influenced by disease etiology.  In 315 patients studied 
in the U.S.  from 1990 to 2001,  good prognosis without 
LT was found in the patients with paracetamol over-
dose,  hepatitis A virus infection,  shock liver,  or preg-
nancy-related ALF in America,  with a short-term sur-
vival of > 50% [24].  In contrast,  in this same series,  the 
patients with an indeterminate cause or non-parac-
etamol drug-related ALF,  HBV infection,  auto-im-
mune-hepatitis,  Wilson’s disease,  or Budd-Chiari syn-
drome had a short-term transplant-free survival of 25% 
[24].
The distribution of ALF etiology is different between 
Eastern and Western countries.  The most common 
cause of ALF in the Western countries is drug-induced,  
whereas that in Eastern countries in viral infection.  In 
our presentstudy,  the etiology of ALF also included 
“unknown” and viral infection.  Recent advances in LT 
and critical care have improved resulted in improved 
the 1-year survival rate after LT to 60-80% [4-6].  Thus,  
LT is one of the most efficacious treatment modalities 
for ALF.  However,  the operative risk and the necessary 
lifelong immunosuppressive maintenance continue to 
limit the overall efficacy of this approach.  In the setting 
of organ donor shortages,  especially in Japan,  the 
issues of whether or not LDLT can become a substitute 
for cadaveric LT is a serious problem.  Thus,  the accu-
rate assessments of the indications for LT is very 
important when considering the management of ALF.
The efficacy of LDLT for ALF at institutions in east-
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ern Asian countries has been reported [9 , 10 , 13 , 14 ,  
25-27].  In our present study’s patient series treated at 
our university hospital,  the 1-year survival rate after 
LDLT was 87.5%,  which is comparable to that of non-
ALF patients.  Further,  all survivors completely recov-
ered from their physical deterioration without neuro-
logical sequelae,  even in some of the patients suffering 
from severe grade IV encephalopathy.  The optimal 
timing of transplant intervention and adequate critical 
care can enhance outcomes.  Even in patients with rap-
idly progressive cerebral edema,  hemodiafiltration with 
a high-performance membrane combined with plasma 
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Table 2　 Univariate analysis of variables between the LDLT survivors and non-survivors
Survivors (n＝21) Deaths (n＝3) P value
Age (years) 41.8±2.9 29.3±4.7 0.105a
Gender
　Male : Female 6 : 15 2 : 1 0.205b
Etiology 0.61b
　Viral hepatitis 8 2
　Drug induced 11 1
　Cryptogenic 2 0
Disease Type 0.56b
　Acute type : sub-acute type : LOHF 15 : 5 : 1 3 : 0 : 0
O-C (days) 11.7±3.4 7.3±1.2 0.48a
PT (%) 25.3±1.9 23.8±3.1 0.89a
TB (mg/dL) 13.6±1.6 12.5±3.7 0.06a
D/T ratio 0.49±0.04 0.48±0.09 0.82a
PLT (104/µL) 9.5±1.3 3.96±1.91 0.09a
Grade of hepatic encephalopathy
　II : III : IV 7 : 11 : 3 1 : 2 : 0 0.76b
Donor age (years) 37.2±11.4 58±6.9 0.02a
Donor gender
　Male : Female 12 : 9 3 : 0 0.079b
ABO compatibility
　Identical : compatible : incompatible 14 : 6 : 1 1 : 2 : 0 0.49b
Donor relation
　Patients : Siblings : Children : Spouse 5 : 6 : 7 : 3 2 : 1 : 0 : 0 0.265b
Graft type
　Right lobe : Left lobe : Posterior sector 13 : 7 : 1 1 : 2 : 0 0.52b
GW/RBW ratio 0.99±0.25 0.73±0.24 0.05a
Operating time (min) 543±28.5 462±37.5 0.44a
Blood loss (mL/kg) 100±111.5 35.4±7.5 0.56a
†Values are expressed as mean ± standard deviation (S.D.).
a Wilcoxon signed-rank test.  bχ2 test.
D/T ratio,  ratio of direct to total bilirubin concentration; GW/RBW ratio,  ratio of donor graft weight to recipient body weight; LOHF,  late 
onset hepatic failure; O-C,  the interval between hepatitis onset and hepatic encephalopathy development; PT,  prothrombin time; TB,  
total bilirubin; PLT,  platelet count.
exchange may prevent irreversible brain damage and act 
as a bridge to LT [28].
In our series of 24 patients,  there was one ABO-
incompatible case,  in which anti-CD20 targeting agent 
and plasma exchange was employed to lower the anti-
body titers and thereby minimize early graft failure [29-
31].  In another report,  prompt induction therapy by 
plasma exchange during apheresis therapy enabled 
successful alternative transplant procedures in a case in 
which an appropriate ABO-compatible or -identical 
donor was not available [31 , 32],  and the deaths at all 
three hospitals in those studies resulted from postoper-
ative septic complications,  biliary complications,  and 
fungal infections.  Each of the patients failed to recover 
from sepsis and subsequently developed multiple organ 
failure.  The univariate analysis identified 2 preoperative 
risk factors: older donor age and small-for-sized graft.
Post-transplant morbidity and mortality vary 
according to the quality of the graft and the blood-
group compatibility between donors and recipients 
[4 , 33].  The quality of a graft is dependent on various 
factors,  including the age of the donor,  the steatosis of 
the donor’s liver,  and the ratio of the graft volume to the 
recipient’s standard liver volume.  Though our patient 
number was small,  these risk factors were compatible 
with those of previous reports.  It is important to select 
a donor and graft on the basis of the recipient status.
In this study,  one of the poor prognostic factors was 
donor age,  of which the cut-off value of which was 
50-years old.  The graft function from older donors in 
LT remains controversial [34 , 35].  The cytochrome 
P-450 content of the liver declines by 16% from the age 
of 40 years to 69 years and by 32% after the age of 70 
years.  The impairment of energy-dependent and 
microtubule-dependent transport processes with aging 
results in a 35-40% decrease in hepatic arterial flow and 
a 50% decrease in bile flow,  respectively [36].  Poor 
prognosis associated with aged liver grafts may be due to 
an overexpression of p-STAT3 and refractory responses 
in liver regenerating after transplantation [37].  In addi-
tion,  p66 (Shc),  known as an age-/oxidant-associated 
protein,  played a pivotal role in the impairment of liver 
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Fig. 2　 Sensitivities for the indication for liver transplantation in comparison of (A) the new Japanese guidelines and the Kingʼs College 
Hospital criteria,  and (B) the new Japanese guidelines and the previous Japanese guidelines.
regeneration by triggering oxidative stress and subse-
quent liver injury (apoptosis) in aged mice [38].  In light 
of those findings,  it is crucial that clinicians take into 
account the sufficient graft volume,  and donor age,  and 
functional quality of liver graft.
Various prognostic and predictive criteria have been 
used to determine the indications for liver transplanta-
tion for ALF,  including the King’s College Hospital cri-
teria [6] and the Clinchy’s criteria [39].  The King’s 
College Hospital criteria incorporate both the etiology 
of ALF (acetaminophen-induced ALF versus non-acet-
aminophen induced ALF) and the clinical parameters of 
disease,  but these criteria appear to have worse negative 
predictive values (70-90% in acetaminophen-induced 
ALF and 25-50% in non-acetaminophen-induced ALF).  
The King’s College Hospital criteria are helpful in iden-
tifying patients who may need LT; hence,  up to 20% of 
those meeting these criteria could have survived with-
out orthotopic liver transplantation,  and those not 
meeting these criteria may still require transplantation 
[40].
Although acetaminophen is the major cause of ALF 
in Europe and the U.S.,  hepatitis viral infection is the 
most frequent cause of ALF in East Asian countries 
[41].  Thus,  ALF has been typically represented by ful-
minant hepatitis in Japan,  and the diagnostic criteria for 
“fulminant hepatitis” were established at the Inuyama 
Symposium in 1981.  These diagnostic criteria were dif-
ferent from those in Europe and the U.S.  Thus,  the 
guidelines to determine the indications for liver trans-
plantation for ALF may not necessarily be applicable to 
fulminant hepatitis in countries with different back-
grounds and etiologies.  In Japan,  the indications for 
liver transplantation in ALF are currently determined 
according to the guidelines published by the Acute Liver 
Failure Study Group of Japan in 1996 [42].
However,  the predictive accuracy of these guidelines 
declined in patients with ALF seen between 1998 and 
2003; 68% and 78% in the acute and sub-acute typed 
ALF,  respectively,  and the values did not improve fol-
lowing reassessment at 5 days later [41].  Later,  the 
same Study Group established a novel scoring system to 
predict the outcome of patients with ALF,  and the sys-
tem was reported as applicable predictive criteria for LT 
[19 , 43].  Comparing the sensitivities between the 2 sets 
of prognostic criteria (King’s College Hospital criteria 
and the new Japanese guidelines),  the new Japanese 
guidelines may be superior to the King’s College Hospital 
criteria in terms of increased accuracy for the determi-
nation of indications for LT,  especially in patients with 
acute-type ALF.  Although the King’s College Hospital 
criteria are an indispensable prognostic tool,  the sensi-
tivity of these criteria depends on the etiologies and 
disease type of ALF.  Viral hepatitis is the most common 
cause of ALF in Japan,  Korea,  Hong Kong,  and Spain,  
whereas acetaminophen is the leading cause of ALF in 
the U.S.  and the UK [25 , 44-47].  In these features of 
etiology according to location,  it could thus be appro-
priate that a variety of prognostic criteria are used on 
different occasions.
The indications and eligibility for LT should be 
assessed as early as possible,  because ALF can rapidly 
lead to death.  The results of our present study using the 
new Japanese guidelines can predict the indications for 
LT at the time of the onset of encephalopathy.  Thus,  the 
new Japanese guidelines could be a novel and reliable 
predictive tool for the designation of treatment for ALF.  
However,  it is an established fact that these guidelines 
and criteria may not necessarily predict the prognosis 
and adequate treatment modality for ALF patients,  
especially in some specific ALF types.  In those cases,  
the treatment strategy should be designed on the basis 
of a diversified criteria and the assessment of the 
patients’ status and dynamic life-threatening changes.
This study has some limitations.  This study was a 
retrospective analysis with a small patient number at a 
single institution.  We focused on only transplant cases 
of ALF and did not include non-transplant cases.  
Further analysis of patient cohorts with various treat-
ment modalities and outcomes in several transplant 
programs should be conducted.
In conclusions,  an expansion of the donor pool is 
expected,  and LDLT plays a key role in the manage-
ment of patients with rapidly progressive ALF.  The new 
Japanese guidelines can be used to determine the indi-
cations for LT with a simple scoring system,  and these 
guidelines are a good alternative to the previous crite-
ria.
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